gorodenkoff
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said their medicine datopotamab deruxtecan (Dato-DXd) in combination with Merck's (MRK) Keytruda (pembrolizumab), with or without platinum chemotherapy, showed promising clinical activity and a tolerable safety profile in certain patients